Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. All patients received 500 mg of hydroxyurea t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Reardon, David A., Norden, Andrew D., Desjardins, Annick, Vredenburgh, James J., Herndon, James E., Coan, April, Sampson, John H., Gururangan, Sridharan, Peters, Katherine B., McLendon, Roger E., Norfleet, Julie A., Lipp, Eric S., Drappatz, Jan, Wen, Patrick Y., Friedman, Henry S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616615/
https://ncbi.nlm.nih.gov/pubmed/21938530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0687-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak